ATRY Atrys Health, S.A.
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.…
Industry Peers
BiotechnologyKey Statistics
About Atrys Health (BME: ATRY)
›
Atrys Health (BME: ATRY) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 763 employees.
The shares were at 2.570 EUR on 19 November 2026, down 4.1% over 52 weeks. Its 52-week range is 2.310 EUR to 3.190 EUR: the price is 19.4% below the high and 11.3% above the low.
Its market capitalisation is 195.11M EUR.
Atrys Health reports return on equity of -66.0%, an operating margin of -5.2% and revenue up 9.4% year over year.
Its debt exceeds its cash by 105.59M EUR, a debt-to-equity ratio of 1.70. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 4.933 EUR is 92.0% above the current price.